Showing 1911-1920 of 5643 results for "".
- Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenavahttps://modernod.com/news/outlook-therapeutics-reports-positive-safety-profile-from-norse-three-study-for-lytenava/2479037/Outlook Therapeutics announced positive topline results from its NORSE THREE open-label safety study evaluating ONS-5010/Lytenava (bevacizumab-vikg) to treat retinal diseases. Topline results from the open-label safety study demonstrated that ONS-5010 showed no unexpecte
- New Open Access Ophthalmology Journal Now Livehttps://modernod.com/news/new-open-access-ophthalmology-journal-now-live/2478998/Ophthalmology Science—the American Academy of Ophthalmology’s first open access journal—is now live and accepting submissions. Ophthalmology Science is an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory
- National Eye Institute Launches Data Portal for Macular Degeneration Researchhttps://modernod.com/news/national-eye-institute-launches-data-portal-for-macular-degeneration-research/2478992/The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease
- Johnson & Johnson Vision Introduces Acuvue Oasys Multifocal with Pupil Optimized Designhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-oasys-multifocal-with-pupil-optimized-design/2478970/Johnson & Johnson Vision has introduced a new eye care option for patients with presbyopia: Acuvue Oasys Multifocal Contact Lenses with Pupil Optimized Design. The new lens is now available in the United States and Canada.
- Zubisoft Launches New Nomogram and Laser Treatment Planner for Zeiss SMILEhttps://modernod.com/news/zubisoft-launches-new-nomogram-and-laser-treatment-planner-for-zeiss-smile/2478920/Swiss-based Zubisoft has developed the IBRA nomogram calculator, designed to allow refractive surgeons to optimize treatment planning for small incision lenticular extraction with the Zeiss VisuMax femto laser platfor
- New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Beyond Acute Disease into Chronic Phasehttps://modernod.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the North American Neuro-Ophthalmology Society (NANOS) 2021 Virtual Annual Meeting. Findings demonstrate that TED not only has a significant burden on patients during the acute (activ
- Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operationshttps://modernod.com/news/bausch-health-to-reduce-debt-by-100-million-using-cash-generated-from-operations/2478894/Bausch Health announced it will reduce debt by $100 million through the redemption of outstanding senior secured notes, using cash generated from operations. “As Bausch Health continues its recovery from the effects of the COVID-19 pandemic, we also rema
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.